Boston optimistic for coming years after strong 2004
This article was originally published in Clinica
Executive Summary
Boston Scientific has set itself ambitious sales and earnings targets for the coming three years, signalling its confidence that its drug-eluting stent (DES) franchise will be able to hold its ground in the face of increasing competition. The firm cornered 63% of the US DES market and 55% of the world market in the fourth quarter of 2004, in terms of dollar sales.